GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Accounts Receivable

Gensight Biologics (XPAR:SIGHT) Accounts Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Gensight Biologics's accounts receivables for the quarter that ended in Dec. 2023 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Gensight Biologics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €-0.58.


Gensight Biologics Accounts Receivable Historical Data

The historical data trend for Gensight Biologics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Accounts Receivable Chart

Gensight Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.05 0.75 - -

Gensight Biologics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.31 - 0.04 -

Gensight Biologics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Gensight Biologics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Gensight Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.001/-0.283*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Gensight Biologics's accounts receivable are only considered to be worth 75% of book value:

Gensight Biologics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.134+0.75 * 0.001+0.5 * 0-39.8
-0-0)/64.9657
=-0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Gensight Biologics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Gensight Biologics (XPAR:SIGHT) Business Description

Traded in Other Exchanges
Address
74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines